Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

AGIO April 29, 2026

Agios Pharmaceuticals Q1 2026 Earnings Call - AQVESME Launch Momentum Accelerates, sNDA Filing Set for Q2

Agios Pharmaceuticals delivered a strong start to 2026 with $20.7 million in Q1 net revenues, driven by the U.S. commercial launch of AQVESME for thalassemia. The company reported 242 prescriptions wr...

  • 1. Q1 2026 net revenues reached $20.7 million, a 138% year-over-year increase, primarily driven by the U.S. commercial launch of AQVESME in thalassemia, with $18.8 million from U.S. sales.
  • 2. The company reported 242 prescriptions written by REMS-certified physicians as of March 31, up from 44 at the end of January, indicating strong early demand despite the REMS program only becoming operational in late January.
  • 3. Management cautioned against extrapolating Q1 prescription volumes into a steady run rate, noting that early adoption is concentrated among highly motivated, transfusion-dependent patients, and initiation timelines are expected to normalize to 10-12 weeks as the launch broadens.
  • +9 more takeaways
OTLY April 29, 2026

Oatly Q1 2026 Earnings Call - Growth Playbook Works, Middle East Conflict Caps EBITDA Guidance

Oatly delivered a solid Q1 2026 with revenue up 15.6% and adjusted EBITDA turning positive at SEK 5 million, driven by a refreshed growth playbook focused on taste and health. The strategy is gaining ...

  • Revenue grew 15.6% year-over-year, or 8.1% in constant currency, driven by 5.6% volume growth and a 2.5% positive price/mix contribution.
  • Adjusted EBITDA turned positive at SEK 5 million, an improvement of SEK 8.7 million versus Q1 2025, reflecting strong top-line growth and 188 basis points of gross margin expansion.
  • Gross margin reached 33.4%, up 188 basis points year-over-year, fueled by fixed cost absorption, supply chain efficiencies, and favorable product/channel mix.
  • +7 more takeaways
EXTR April 29, 2026

Extreme Networks Q3 FY2026 Earnings Call - Platform ONE SaaS Acceleration and Supply Chain Resolution Drive Record Margins

Extreme Networks delivered a fifth straight quarter of double-digit revenue growth, with Q3 FY2026 revenue of $317 million beating guidance and rising 11% year-over-year. The standout metric is SaaS A...

  • Revenue of $317 million exceeded the high end of guidance, marking a fifth consecutive quarter of double-digit year-over-year growth at 11%.
  • SaaS ARR accelerated sharply to $236 million, up 29% year-over-year, driven by strong Platform ONE attach rates and upselling within the existing customer base.
  • Gross margins expanded to 62.3%, beating guidance, as selective price increases and disciplined cost management offset component inflation.
  • +7 more takeaways
DQ April 29, 2026

Daqo New Energy Q1 2026 Earnings Call - Management Halts Sales Below Cost, Betting on June Policy Enforcement

Daqo New Energy reported a deep Q1 2026 loss as polysilicon prices collapsed below production costs, prompting management to halt external sales and build inventory. The company is holding its utiliza...

  • Management halted external polysilicon sales after prices fell below production costs, prioritizing inventory accumulation over revenue generation.
  • Q1 2026 net loss widened to $88.4 million, driven by a $98.4 million inventory impairment provision and collapsing average selling prices.
  • Company maintains a fortress balance sheet with $2 billion in liquid assets and zero debt, positioning it to weather the industry downturn longer than leveraged peers.
  • +7 more takeaways
BG April 29, 2026

Bunge Global Q1 2026 Earnings Call - Raised Full-Year EPS Guidance on Biofuel Tailwinds and Viterra Synergies

Bunge Global delivered a first quarter that outpaced management’s own expectations, driven by a surge in soybean and soft seed processing margins and a favorable policy environment for U.S. biofuels. ...

  • Bunge Global raised full-year 2026 adjusted EPS guidance to $9.00-$9.50, up from the previous $7.50-$8.00 range, citing strong Q1 execution and favorable biofuel demand.
  • First quarter adjusted EPS came in at $1.83, beating the prior year’s $1.81, while reported EPS of $0.35 was suppressed by a $1.28 per share unfavorable mark-to-market timing difference.
  • Soybean and soft seed processing segments drove the beat, fueled by higher processing volumes in Argentina and Brazil, and resilient refining premiums across North America and Europe.
  • +7 more takeaways
LMND April 29, 2026

Lemonade Q1 2026 Earnings Call - AI-Driven Leverage and Pet Insurance Milestone Fuel Profitability Surge

Lemonade delivered a quarter defined by accelerating growth and rapidly improving unit economics. In-force premium jumped 32% to $1.33 billion, while revenue surged 71% thanks to a favorable reinsuran...

  • In-force premium grew 32% year-over-year to $1.33 billion, marking the 10th consecutive quarter of accelerating growth.
  • Revenue surged 71% to $258 million, driven by a reinsurance transition that significantly increased premium retention.
  • Gross profit jumped 159% to $100 million, reflecting the combination of top-line expansion and underwriting discipline.
  • +7 more takeaways
CMRE April 29, 2026

Costamare Inc Q1 2026 Earnings Call - Secures $2.8B in New Contracts with COSCO While Boosting Dividend

Costamare Inc. delivered a strong first quarter in 2026, posting adjusted net income of $76 million and ending the period with $645 million in liquidity. The shipping company is aggressively expanding...

  • Costamare reported Q1 2026 adjusted net income of $76 million ($0.63 per share), demonstrating strong near-term profitability.
  • The company secured 16 newbuilding contracts with COSCO Shipping, adding $2.8 billion in incremental contracted revenue over 15 to 8-year charters.
  • Total contracted revenues now stand at $6.2 billion, with a TEU-weighted remaining charter duration of 6.1 years, providing exceptional cash flow visibility.
  • +7 more takeaways
AMRN April 29, 2026

Amarin Corporation Q1 2026 Earnings Call - Vascepa Prescriptions Surge 17% Amid European Partnership Launch and Cash Flow Turnaround

Amarin Corporation delivered a decisive pivot in Q1 2026, transforming from a cash-burner into a cash-flow-positive entity while accelerating its global commercial strategy. The company reported $45.1...

  • U.S. Vascepa-branded prescriptions rose 17% year-over-year in Q1 2026, with the company capturing 48% of the total icosapent ethyl market as generic competition continues to reshape the landscape.
  • Total net revenue reached $45.1 million, supported by a 113% quarter-over-quarter increase in European revenue to $4.9 million under the new partnership model with Recordati.
  • Amarin achieved its second consecutive quarter of positive operating cash flow, generating $6.4 million in Q1 2026 and ending with a debt-free balance sheet and $308 million in cash.
  • +7 more takeaways
VIRT April 29, 2026

Virtu Financial Q1 2026 Earnings Call - Record Trading Income Driven by Capital Expansion and Execution Services Momentum

Virtu Financial delivered a historic first quarter in 2026, posting record Adjusted Net Trading Income of $787 million. The result was not a fluke of favorable volatility but a direct function of a de...

  • Record Q1 2026 performance: Adjusted Net Trading Income hit $787 million ($12.9 million per day), an all-time quarterly high for the firm.
  • Aggressive capital expansion: Virtu added over $500 million in new trading capital in the last seven months, maintaining a return on total capital exceeding 100%.
  • Execution Services momentum: The VES segment reported $2.5 million per day in NT, marking eight consecutive quarters of growth and serving as a key diversification engine.
  • +7 more takeaways
BLKB April 29, 2026

Blackbaud Q1 2026 Earnings Call - Agentic AI Launch Drives New Revenue Streams and Margin Expansion

Blackbaud reported a strong start to fiscal 2026 with Q1 organic revenue growth of 4.2% to $281 million and non-GAAP EPS rising 20% to $1.14. The company is betting heavily on its new "Agents for Good...

  • Q1 2026 organic revenue grew 4.2% year-over-year to $281 million, reflecting steady demand for mission-critical software in the social impact sector.
  • Non-GAAP EPS rose 20% to $1.14, beating expectations and demonstrating the impact of cost management and operational efficiency improvements.
  • Free cash flow surged nearly 50% year-over-year to $37 million, providing ample liquidity for continued investment and capital return to shareholders.
  • +7 more takeaways